Date: 2014-10-21
Type of information: Nomination
Compound: head of clinical development, head of biology
Company: Karus Therapeutics (UK)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 21, 2014, Karus Therapeutics announced that it has further strengthened its R&D team with two new appointments; Dr Simon Roitt, who joins as Head of Clinical Development and Dr Peter Finan, who has been appointed as Karus’s Head of Biology.
Dr Roitt, who joined Karus in August, brings 20 years’ of clinical development experience in the healthcare sector with previous senior roles at Roche, GE Healthcare and Biocompatibles International. His experience in leading clinical teams in global multifunctional pharma environments will be critical for his role at Karus where he will implement the Company’s clinical development plans.
Dr Finan took up his new position as Head of Biology in September following an extensive career in the pharmaceutical industry, from target discovery through to early clinical development in oncology and inflammatory disease. He joins Karus from Novartis, where he held a number of senior roles over a period of 16 years, during which time he worked on, amongst others, the PI3K pathway. Karus’s most advanced programme is a PI3K-p110?/? dual inhibitor for the treatment of inflammatory disorders and Dr Finan’s experience will help to accelerate the translation of this programme into the clinic.
Financial terms:
Latest news:
Is general: Yes
